Allan P. Marchington

Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA.

Serentis Ltd. discovered, developed and distributed pharmaceutical products. The company was founded by Tim Sharpington, Alan Rothaul, and Andy Baxter in 2006 and was headquartered in London, the United Kingdom.

PharmaKodex Ltd. develops pharmaceuticals products. It uses oral and transdermal drug delivery technologies to develop improved medicinal products. It develops and commercializes its products and technologies in an overlapping two component process. The company was founded in 2005 and is headquartered in Chippenham, UK

Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Part of Dassault Systèmes SA, Cambridge Combinatorial Ltd. is a company engaged in the design, production and supply of compounds for the pharmaceutical industry. The company is based in Cambridge, UK. Cambridge Combinatorial was acquired by Oxford Molecular Group Plc on October 15, 1998 for $20.78 million. The British company was founded by Allan P. Marchington.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom.